Lupus & antiphospholipid syndrome
Mortality in patients with systemic lupus erythematosus: A meta-analysis of overall and cause-specific effects
Pooled result · All-cause mortality SMRResult — go to the resultSMR 2.866 95% CI 2.490–3.242Authors' conclusion
This meta-analysis underscores a significant 2.87-fold elevation in the SMR among patients with SLE compared to the general population, transcending differences in sex or geographical regions.
Study context
- Population
- Patients diagnosed with systemic lupus erythematosus (SLE); studies from PUBMED, EMBASE and Cochrane
- Participants
- 72,342 patients29 studies
- Comparison
- Patients with SLE vs the general population
- SLEn = 72,342
- Outcome
- All-cause SMR
Pooled result
All-cause mortality SMR
SMR
2.866
95% CI 2.490–3.242
P < 0.001
As reported in the abstract
Further pooled results
All-cause SMR by region
- Europe: all-cause SMR
- 2.607 (95% CI 1.939-3.275; p < .001)
- Asia: all-cause SMR
- 3.043 (95% CI 2.082-4.004; p < .001)
- Particularly high standardized mortality ratios (SMRs) noted in North America and Oceania
All-cause SMR by sex (pooled)
- Females: pooled SMR
- 3.261 (95% CI 2.674-3.848; p < .001)
- Males: pooled SMR
- 2.747 (95% CI 2.190-3.304; p < .001)
Cause-specific SMRs
- Renal disease: SMR
- 4.486 (95% CI 3.024-5.948; p < .001)
- Infections: SMR
- 4.946 (95% CI 4.253-5.639; p < .001)
- Cardiovascular diseases (CVD): SMR
- 2.931 (95% CI 1.802-4.061; p < .001)
- Cerebrovascular accidents (CVA): SMR
- 1.588 (95% CI 0.647-2.528; p = .001)
- Cancer: SMR
- 1.698 (95% CI 0.871-2.525; p < .001)
Original publication
Mortality in patients with systemic lupus erythematosus: A meta-analysis of overall and cause-specific effects. Lupus. Published 21 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →